Last reviewed · How we verify
Water for injection
Water for injection is a sterile, pyrogen-free solvent used to dilute or dissolve pharmaceutical substances for parenteral administration.
Water for injection is a sterile, pyrogen-free solvent used to dilute or dissolve pharmaceutical substances for parenteral administration. Used for Diluent for injectable pharmaceutical preparations, Vehicle for parenteral drug administration.
At a glance
| Generic name | Water for injection |
|---|---|
| Also known as | Juhel water for injection, Aqua ad iniectabilia, Sterile Water For Injection, Sterile water |
| Sponsor | Ahmadu Bello University Teaching Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Water for injection serves as a pharmaceutical vehicle and diluent for injectable medications. It is produced through distillation or reverse osmosis to ensure sterility and the absence of pyrogens (fever-inducing substances). It has no direct therapeutic mechanism but is essential for preparing injectable formulations and maintaining drug stability.
Approved indications
- Diluent for injectable pharmaceutical preparations
- Vehicle for parenteral drug administration
Common side effects
- Hypervolemia (fluid overload)
- Hyponatremia (low sodium)
- Local injection site reactions
Key clinical trials
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Voluma (NA)
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (PHASE1, PHASE2)
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes (NA)
- MRI Study of Cerebral Blood Flow in Development Disorders in Children (NA)
- A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (PHASE2)
- Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Water for injection CI brief — competitive landscape report
- Water for injection updates RSS · CI watch RSS
- Ahmadu Bello University Teaching Hospital portfolio CI